SDSarah K. Dutcher

Sarah K. Dutcher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah K. Dutcher has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Empirical application of missing data methods to address confounding in health insurance claims-based analyses using electronic health records available on a subset: an example from the Food and Drug Administration’s sentinel system

    by Gaia Pocobelli, Noorie Hyun, Pamela A Shaw, Laura B Harrington, John G Connolly, Arvind Ramaprasan, Rishi J Desai, Sarah K Dutcher, Hana Lee, Yan Li, et al.

    Health insurance claims-based analyses inform many large epidemiologic studies but may have unmeasured confounding. Electronic health records (EHRs) have more detailed health information, but data may be missing on some individuals. Informed by recent work comparing approaches to address missing data, we selected and applied generalized raking (GR) and multiple imputation (MI) to illustrate how to efficiently combine data from these 2 sources. We considered a previously conducted claims-based study comparing 90-day arterial thromboembolism (ATE) risk among patients hospitalized with COVID-19 versus influenza, for which body mass index (BMI), a potential confounder, was unavailable. Using linked claims-EHR data, we adjusted for the same covariates as the original study and used GR and MI to additionally control for EHR-ascertained BMI, available for a subset. We included 912 hospitalized Kaiser Permanente Washington patients, 449 with COVID-19 and 463 with influenza (31.0% and 38.5% had EHR-ascertained BMI in the prior 90 days, respectively). Adjusted hazard ratios of ATE were similar with and without adjustment for BMI, in GR and MI analyses. In the setting of a claims-EHR–based study with missing data on a potential confounder, we describe our selection of the missing data approach, and its implementation, to demonstrate a broadly applicable process.

  • Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof‐of‐Principle Analysis

    by Sushama Kattinakere Sreedhara, Haritha S. Pillai, Rishi J. Desai, Kerry Ngan, Ken Lai, Joyce Lii, Sarah K. Dutcher, Youjin Wang, Jummai Apata, Fang Tian, et al.

    Claims‐based analyses can suffer from residual and unmeasured confounding due to factors that are poorly captured in claims. Some of these factors may be measured in other data sources, such as in structured fields of electronic health records (EHR), for example, laboratory test results, or in free‐text physician notes. We conducted a proof‐of‐principle study to demonstrate a process for evaluating the potential risk of confounding—factors poorly captured in claims data but measurable in the EHR as part of drug safety surveillance activities. In future practical applications, this approach could be used along with other sensitivity analyses to evaluate potential residual confounding (e.g., E ‐values, negative controls). We used claims‐EHR linked data from the Mass General Brigham site of the US Food and Drug Administration's (FDA) Sentinel Real World Evidence Data Enterprise. We extracted a cohort that was previously used in a prototypical Sentinel claims‐based query that compared initiators of sacubitril‐valsartan vs. angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers on the risk of angioedema. In this cohort, we used EHR data to characterize angioedema risk factors poorly captured in claims and observed that claims‐based proxies balanced most risk factors that were measurable only in EHR data. While quantitative bias analysis methods can be used to adjust for residual confounding using external information on magnitude and direction of bias, this was deemed unnecessary for this example due to the observed balance achieved on risk factors for angioedema measured in the EHR. A robust linked EHR‐claims data infrastructure is crucial for routine application of these methods to evaluate and mitigate residual confounding in drug safety surveillance studies.

  • Transparency, reproducibility, and replicability of pharmacoepidemiology studies in a distributed network environment

    by Ashish Rai, Judith C. Maro, Sarah Dutcher, Patricia Bright, Sengwee Toh

    Purpose: Our objective is to describe how the U.S. Food and Drug Administration (FDA)'s Sentinel System implements best practices to ensure trust in drug safety studies using real‐world data from disparate sources.Methods: We present a stepwise schematic for Sentinel's data harmonization, data quality check, query design and implementation, and reporting practices, and describe approaches to enhancing the transparency, reproducibility, and replicability of studies at each step.Conclusions: Each Sentinel data partner converts its source data into the Sentinel Common Data Model. The transformed data undergoes rigorous quality checks before it can be used for Sentinel queries. The Sentinel Common Data Model framework, data transformation codes for several data sources, and data quality assurance packages are publicly available. Designed to run against the Sentinel Common Data Model, Sentinel's querying system comprises a suite of pre‐tested, parametrizable computer programs that allow users to perform sophisticated descriptive and inferential analysis without having to exchange individual‐level data across sites. Detailed documentation of capabilities of the programs as well as the codes and information required to execute them are publicly available on the Sentinel website. Sentinel also provides public trainings and online resources to facilitate use of its data model and querying system. Its study specifications conform to established reporting frameworks aimed at facilitating reproducibility and replicability of real‐world data studies. Reports from Sentinel queries and associated design and analytic specifications are available for download on the Sentinel website. Sentinel is an example of how real‐world data can be used to generate regulatory‐grade evidence at scale using a transparent, reproducible, and replicable process.


  • Validity of inpatient electronic health record‐based measures of oxygen‐related therapy in the United States: Lessons applicable for studying COVID‐19 endpoints

    by Candace C. Fuller, Edward Rosen, Ashish Rai, Austin Cosgrove, Karla Miller, Patricia Bright, Katherine Haffenreffer, Russell E. Poland, Natasha Pratt, Kenneth Sands, et al.

    Introduction: During the COVID‐19 pandemic, inpatient electronic health records (EHRs) have been used to conduct public health surveillance and assess treatments and outcomes. Invasive mechanical ventilation (MV) and supplemental oxygen (O2) use are markers of severe illness in hospitalized COVID‐19 patients. In a large US system (n = 142 hospitals), we assessed documentation of MV and O2 use during COVID‐19 hospitalization in administrative data versus nursing documentation.Methods: We identified 319 553 adult hospitalizations with a COVID‐19 diagnosis, February 2020–October 2022, and extracted coded, administrative data for MV or O2. Separately, we developed classification rules for MV or O2 supplementation from semi‐structured nursing documentation. We assessed MV and O2 supplementation in administrative data versus nursing documentation and calculated ordinal endpoints of decreasing COVID‐19 disease severity. Nursing documentation was considered the gold standard in sensitivity and positive predictive value (PPV) analyses.Results: In nursing documentation, the prevalence of MV and O2 supplementation among COVID‐19 hospitalizations was 14% and 75%, respectively. The sensitivity of administrative data was 83% for MV and 41% for O2, with both PPVs above 91%. Concordance between sources was 97% for MV (κ = 0.85), and 54% for O2 (κ = 0.21). For ordinal endpoints, administrative data accurately identified intensive care and MV but underestimated hospitalizations with O2 requirements (42% vs. 18%).Conclusions: In comparison to nursing documentation, administrative data under‐ascertained O2 supplementation but accurately estimated severe endpoints such as MV. Nursing documentation improved ascertainment of O2 among COVID‐19 hospitalizations and can capture oxygen requirements in adults hospitalized with COVID‐19 or other respiratory illnesses.

  • Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation

    by Judith C. Maro, Michael D. Nguyen, Joy Kolonoski, Ryan Schoeplein, Ting‐Ying Huang, Sarah K. Dutcher, Gerald J. Dal Pan, Robert Ball

    Congress mandated the creation of a postmarket Active Risk Identification and Analysis (ARIA) system containing data on 100 million individuals for monitoring risks associated with drug and biologic products using data from disparate sources to complement the US Food and Drug Administration's (FDA's) existing postmarket capabilities. We report on the first 6 years of ARIA utilization in the Sentinel System (2016–2021). The FDA has used the ARIA system to evaluate 133 safety concerns; 54 of these evaluations have closed with regulatory determinations, whereas the rest remain in progress. If the ARIA system and the FDA's Adverse Event Reporting System are deemed insufficient to address a safety concern, then the FDA may issue a postmarket requirement to a product's manufacturer. One hundred ninety‐seven ARIA insufficiency determinations have been made. The most common situation for which ARIA was found to be insufficient is the evaluation of adverse pregnancy and fetal outcomes following in utero drug exposure, followed by neoplasms and death. ARIA was most likely to be sufficient for thromboembolic events, which have high positive predictive value in claims data alone and do not require supplemental clinical data. The lessons learned from this experience illustrate the continued challenges using administrative claims data, especially to define novel clinical outcomes. This analysis can help to identify where more granular clinical data are needed to fill gaps to improve the use of real‐world data for drug safety analyses and provide insights into what is needed to efficiently generate high‐quality real‐world evidence for efficacy.


  • Switching patterns of immediate‐release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15–64 years in the United States, 2013–2019

    by Silvia Perez‐Vilar, Maria E. Kempner, Sarah K. Dutcher, Talia J. Menzin, Corinne Woods, Kira Leishear, James Osterhout, Sruthi Adimadhyam, Modupeola Adereti, Amanda Carruth, et al.

    Purpose: Immediate‐release forms of generic mixed amphetamine salts (MAS) have been the subject of passive surveillance reports signaling lack of effectiveness. We examined switching patterns that might suggest whether long‐term users of specific MAS are more likely to switch away or switch back after use of the MAS of interest in the FDA's Sentinel Distributed Database.Methods: We required at least 60‐day continuous supply of selected MAS grouped by Abbreviated New Drug Application (ANDA) to describe patterns of switching away from and to generics approved under the ANDAs of interest among individuals ages 15–64 years with attention deficit hyperactivity disorder or narcolepsy during 2013–2019.Results: We observed the greatest number of treatment episodes for ANDA 040422 (n = 525 771), followed by ANDA 202424 (n = 181 693), ANDA 040439 (n = 62 363), ANDA 040440 (n = 21 143), and ANDA 040480 (n = 8792). Of those with switches away from their original ANDA, episodes initiated on generic products under ANDA 040422 (48.6%) and ANDA 202424 (43.0%) were most likely to switch back, while those initiated on generic product under ANDA 040480 were least likely (24.1%). Of those episodes with switches to a generic under an ANDA of interest, about one‐third (range 27.1% to 37.0%) switched back to the same product. These switches back had a median time to switch of about 30 days.Conclusions: These descriptive analyses, although subject to limitations, did not suggest increased switching away or switching back after use of the generics of interest. Continued post‐marketing surveillance is warranted.

  • Open Access

    Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study

    by Vincent Lo Re, Sarah K Dutcher, John G Connolly, Silvia Perez-Vilar, Dean M Carbonari, Terese A DeFor, Djeneba Audrey Djibo, Laura B Harrington, Laura Hou, Sean Hennessy, et al.

    Objective To measure the 90 day risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with covid-19 in the ambulatory (ie, outpatient, emergency department, or institutional) setting during periods before and during covid-19 vaccine availability and compare results to patients with ambulatory diagnosed influenza. Design Retrospective cohort study. Setting Four integrated health systems and two national health insurers in the US Food and Drug Administration's Sentinel System. Participants Patients with ambulatory diagnosed covid-19 when vaccines were unavailable in the US (period 1, 1 April-30 November 2020; n=272 065) and when vaccines were available in the US (period 2, 1 December 2020-31 May 2021; n=342 103), and patients with ambulatory diagnosed influenza (1 October 2018-30 April 2019; n=118 618). Main outcome measures Arterial thromboembolism (hospital diagnosis of acute myocardial infarction or ischemic stroke) and venous thromboembolism (hospital diagnosis of acute deep venous thrombosis or pulmonary embolism) within 90 days after ambulatory covid-19 or influenza diagnosis. We developed propensity scores to account for differences between the cohorts and used weighted Cox regression to estimate adjusted hazard ratios of outcomes with 95% confidence intervals for covid-19 during periods 1 and 2 versus influenza. Results 90 day absolute risk of arterial thromboembolism with covid-19 was 1.01% (95% confidence interval 0.97% to 1.05%) during period 1, 1.06% (1.03% to 1.10%) during period 2, and with influenza was 0.45% (0.41% to 0.49%). The risk of arterial thromboembolism was higher for patients with covid-19 during period 1 (adjusted hazard ratio 1.53 (95% confidence interval 1.38 to 1.69)) and period 2 (1.69 (1.53 to 1.86)) than for patients with influenza. 90 day absolute risk of venous thromboembolism with covid-19 was 0.73% (0.70% to 0.77%) during period 1, 0.88% (0.84 to 0.91%) during period 2, and with influenza was 0.18% (0.16% to 0.21%). Risk of venous thromboembolism was higher with covid-19 during period 1 (adjusted hazard ratio 2.86 (2.46 to 3.32)) and period 2 (3.56 (3.08 to 4.12)) than with influenza. Conclusions Patients diagnosed with covid-19 in the ambulatory setting had a higher 90 day risk of admission to hospital with arterial thromboembolism and venous thromboembolism both before and after covid-19 vaccine availability compared with patients with influenza.


  • Risk of hospitalized depression and intentional self-harm with brand and authorized generic sertraline

    by Dinci D. Pennap, Richard S. Swain, Emily C. Welch, Justin Bohn, Jennifer G. Lyons, Sarah Dutcher, Andrew D. Mosholder


  • Open Access

    Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data

    by Sheryl A. Kluberg, Laura Hou, Sarah K. Dutcher, Monisha Billings, Brian Kit, Sengwee Toh, Sascha Dublin, Kevin Haynes, Anne Marie Kline, Mahesh Maiyani, et al.

    Purpose: Health plan claims may provide complete longitudinal data for timely, real‐world population‐level COVID‐19 assessment. However, these data often lack laboratory results, the standard for COVID‐19 diagnosis.Methods: We assessed the validity of ICD‐10‐CM diagnosis codes for identifying patients hospitalized with COVID‐19 in U.S. claims databases, compared to linked laboratory results, among six Food and Drug Administration Sentinel System data partners (two large national insurers, four integrated delivery systems) from February 20–October 17, 2020. We identified patients hospitalized with COVID‐19 according to five ICD‐10‐CM diagnosis code‐based algorithms, which included combinations of codes U07.1, B97.29, general coronavirus codes, and diagnosis codes for severe symptoms. We calculated the positive predictive value (PPV) and sensitivity of each algorithm relative to laboratory test results. We stratified results by data source type and across three time periods: February 20–March 31 (Time A), April 1–30 (Time B), May 1–October 17 (Time C).Results: The five algorithms identified between 34 806 and 47 293 patients across the study periods; 23% with known laboratory results contributed to PPV calculations. PPVs were high and similar across algorithms. PPV of U07.1 alone was stable around 93% for integrated delivery systems, but declined over time from 93% to 70% among national insurers. Overall PPV of U07.1 across all data partners was 94.1% (95% CI, 92.3%–95.5%) in Time A and 81.2% (95% CI, 80.1%–82.2%) in Time C. Sensitivity was consistent across algorithms and over time, at 94.9% (95% CI, 94.2%–95.5%).Conclusion: Our results support the use of code U07.1 to identify hospitalized COVID‐19 patients in U.S. claims data.


  • Validation of an electronic algorithm for Hodgkin and non‐Hodgkin lymphoma in ICD‐10‐CM

    by Mara M. Epstein, Sarah K. Dutcher, Judith C. Maro, Cassandra Saphirak, Sandra DeLuccia, Muthalagu Ramanathan, Tejaswini Dhawale, Sonali Harchandani, Christopher Delude, Laura Hou, et al.

    Purpose: Lymphoma is a health outcome of interest for drug safety studies. Studies using administrative claims data require the accurate identification of lymphoma cases. We developed and validated an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM)‐based algorithm to identify lymphoma in healthcare claims data.Methods: We developed a three‐component algorithm to identify patients aged ≥15 years who were newly diagnosed with Hodgkin (HL) or non‐Hodgkin (NHL) lymphoma from January 2016 through July 2018 among members of four Data Partners within the FDA's Sentinel System. The algorithm identified potential cases as patients with ≥2 ICD‐10‐CM lymphoma diagnosis codes on different dates within 183 days; ≥1 procedure code for a diagnostic procedure (e.g., biopsy, flow cytometry) and ≥1 procedure code for a relevant imaging study within 90 days of the first lymphoma diagnosis code. Cases identified by the algorithm were adjudicated via chart review and a positive predictive value (PPV) was calculated.Results: We identified 8723 potential lymphoma cases via the algorithm and randomly sampled 213 for validation. We retrieved 138 charts (65%) and adjudicated 134 (63%). The overall PPV was 77% (95% confidence interval: 69%–84%). Most cases also had subtype information available, with 88% of cases identified as NHL and 11% as HL.Conclusions: Seventy‐seven percent of lymphoma cases identified by an algorithm based on ICD‐10‐CM diagnosis and procedure codes and applied to claims data were true cases. This novel algorithm represents an efficient, cost‐effective way to target an important health outcome of interest for large‐scale drug safety and public health surveillance studies.